cHCC‐CCA

Elizabeth M. Brunt, Shinichi Aishima(Saga University), Pierre–Alain Clavien(University Hospital of Zurich), Kathryn J. Fowler, Zachary Goodman(Inova Health System), Gregory J. Gores(Mayo Clinic in Arizona), Annette S.H. Gouw(University Medical Center Groningen), Alex Kagen(St. Luke's-Roosevelt Hospital Center), David S. Klimstra(Memorial Sloan Kettering Cancer Center), Mina Komuta(UCLouvain), Fukuo Kondo(Teikyo University), Rebecca A. Miksad(Deaconess Hospital), Masayuki Nakano, Yasuni Nakanuma(Fukui-ken Saiseikai Hospital), Irene Oi‐Lin Ng(University of Hong Kong), Valérie Paradis(Hôpital Beaujon), Young Nyun Park(Yonsei University), Alberto Quaglia(King's College Hospital), Massimo Roncalli, Tania Roskams(KU Leuven), Michiie Sakamoto(Keio University), Romil Saxena(Indiana University), Christine Sempoux(University of Lausanne), Claude B. Sirlin(University of California, San Diego), Ashley Stueck(Dalhousie University), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Wilson M. S. Tsui(Caritas Medical Centre), Xin Wei Wang(National Cancer Institute), Aileen Wee(National University of Singapore), Hirohisa Yano(Kurume University), Matthew M. Yeh(University of Washington), Yoh Zen(Kobe University), Jessica Zucman‐Rossi(Université Paris Cité), Neil D. Theise(New York University)
Hepatology
January 23, 2018
Cited by 329Open Access
Full Text

Abstract

Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as "combined (or mixed) hepatocellular-cholangiocarcinoma." These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. CONCLUSION: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).


Related Papers

No related papers found

Powered by citation graph analysis